Shares of Synairgen plc (SNG.L) were gaining more than 5 percent in the morning trading in London after the respiratory company developing SNG001 reported positive findings from the analysis of data from 60 and 90-day follow-up visits from the Phase 3 SPRINTER trial in patients hospitalised with COVID-19.
SNG001 is an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta. The analysis from the trial in hospitalised COVID-19 patients showed that when compared to placebo, SNG001 reduced the relative risk of recognised symptoms of Long COVID at day 60 and/or day 90.
The company will present full analysis, including several patient-reported outcome measures, which is ongoing, at IDWeek 2022 to be held 19-23 October 2022 in Washington, D.C. The analysis will be submitted for publication in a peer-reviewed journal.
Chris Brightling, NIHR Senior Investigator, Department of Respiratory Sciences at the University of Leicester, said, "While it merits further investigation, it is exciting to see that SNG001 may have a positive effect in reducing some of the most recognised and problematic symptoms associated with Long COVID which afflicts millions of people and for which there are no current treatments."
SNG001 is not approved for use anywhere in the world.
In London, Synairgen shares were trading at 21.48 pence, up 5.42 percent.
For comments and feedback contact: editorial@rttnews.com
Business News